Supernus Pharmaceuticals (NASDAQ: SUPN) received a Buy rating and a $61 price target from Mizuho Securities analyst Irina Rivkind Koffler today. The company’s shares opened today at $47.70.
Rivkind Koffler said:
“We initiate coverage with a Buy rating and $61 PT. We believe Supernus is well-positioned in an attractive CNS market, with a promising pipeline that can drive growth through pending Trokendi XR competition in migraine.”
According to TipRanks.com, Koffler is a 4-star analyst with an average return of 11.3% and a 46.6% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Eagle Pharmaceuticals Inc, and Pacira Pharmaceuticals.
Supernus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $56.50, a 18.4% upside from current levels. In a report issued on September 13, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $56 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $61.25 and a one-year low of $33.30. Currently, Supernus Pharmaceuticals has an average volume of 794.4K.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy.
